Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1

Conditions

Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Arsenic × Clear all
NCT06982274 2025-05-30

IC-APL2020

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
115 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04695223 2021-01-06

Arsenic Trioxide for Structural p53 Mutations

Shanghai Changzheng Hospital

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT03381781 2018-01-04

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Ruijin Hospital

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡